The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02305186
Recruitment Status : Unknown
Verified August 2021 by Craig L Slingluff, Jr, University of Virginia.
Recruitment status was:  Recruiting
First Posted : December 2, 2014
Last Update Posted : August 13, 2021
Sponsor:
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline resectable pancreatic cancer. In general, pancreatic cancer that cannot be removed by surgery is sometimes treated with chemotherapy and radiation therapy, called neoadjuvant treatment, to shrink the tumor so that surgery might be possible. However, this is not always effective at shrinking the tumor enough to allow it to be removed with surgery. Recent discoveries suggest that the investigators own immune system might have a role in controlling the growth of tumors. Drugs such as pembrolizumab can stimulate the immune system against cancer. The purpose of this study is to investigate whether pembrolizumab can be used safely during neoadjuvant treatment and can improve the body's immune response against pancreatic cancer.

Pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is not approved by the U.S. Food and Drug Administration (FDA) for this purpose.


Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: Pembrolizumab Radiation: Neoadjuvant Chemoradiation Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Multicenter Ib/II Study to Assess the Safety & Immunological Effect of Chemoradiation Therapy in Combination With Pembrolizumab Compared to CRT Alone Resectable/Borderline Resectable Pancreatic Cancer
Study Start Date : March 2015
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Neodjuvant CRT + Pembrolizumab
Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
 Drug: Pembrolizumab
Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
Other Names:
  • MK-3475
  • Keytruda

Radiation: Neoadjuvant Chemoradiation
Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
Active Comparator: Neoadjuvant CRT
Standard neoadjuvant chemoradiation treatment (CRT) alone
 Radiation: Neoadjuvant Chemoradiation
Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Tumor Infiltrating Lymphocytes (TILs) per high powered field (hpf) in pancreatic tissue (resected tissue). [ Time Frame: 2-3 years ]
  2. Safety: Incidence of Dose-Limiting Toxicities (DLTs) [ Time Frame: 2-3 years ]

Secondary Outcome Measures :
  1. Disease-free survival (DFS) [ Time Frame: 2-4 years ]
  2. Overall survival (OS) [ Time Frame: 2-4 years ]
  3. Response Rate (RR) [ Time Frame: 2-3 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.
  2. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
  3. Adequate organ function
  4. In subjects requiring biliary decompression, metal stent or drainage using percutaneous transhepatic cholangiogram (PTC) are allowed

Exclusion Criteria:

  1. Immunodeficiency or taking steroid or any other form of immunosuppressive therapy
  2. Has a plastic biliary stent for decompression
  3. Metastatic disease
  4. Prior treatment for pancreatic cancer (other than 4-8 cycles of Folfirinox) or prior treatment with radiation for other diagnoses to the expected pancreatic cancer treatment area
  5. Active autoimmune disease
  6. Pregnancy or Nursing
  7. Known history of Human Immunodeficiency Virus (HIV) or Hepatitis B or C
  8. Prior monoclonal antibody within 4 weeks prior to study Day 1
  9. Known additional malignancy that is progressing or requires active treatment
  10. Evidence of interstitial lung disease or active, non-infectious pneumonitis
  11. Active infection requiring systemic therapy
  12. Prior therapy with an anti-Program Death (PD-1) antibody, anti-PD-L1, anti-PD-L2, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02305186


Contacts
Layout table for location contacts
Contact: Justin Alicea 434-243-5350 xzy7tw@virginia.edu
Contact: Katie Rea 434-924-8574 kaw3j@virginia.edu

Locations
Layout table for location information
United States, Arizona
Mayo Clinic Cancer Center Recruiting
Phoenix, Arizona, United States, 85054
Contact: Justin Weber    855-776-0015      
Contact       weber.justin@mayo.edu   
Principal Investigator: Chee-Chee Stucky, MD         
United States, Connecticut
Hartford HealthCare Recruiting
Hartford, Connecticut, United States, 06102
Contact: Leah Persky       leah.persky@hhchealth.org   
Principal Investigator: Rawad Elias, MD         
United States, Florida
University of Miami Completed
Miami, Florida, United States, 33136
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Katherine Metayer    617-632-6316    KatherineA_Metayer@DFCI.HARVARD.EDU   
Contact: Osama Rahma, MD       OsamaE_Rahma@DFCI.HARVARD.EDU   
Principal Investigator: Osama Rahma, MD         
United States, Texas
MD Anderson Recruiting
Houston, Texas, United States, 77030
Contact: Edsel Esquivel       EFEsquivel@mdanderson.org   
Principal Investigator: Matthew Katz, MD         
Sub-Investigator: Gauri Varadhachary, MD         
United States, Virginia
University of Virginia Cancer Center Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Adela Mahmutovic       am6bd@hscmail.mcc.virginia.edu   
Principal Investigator: Todd Bauer, MD         
Sponsors and Collaborators
Craig L Slingluff, Jr
Investigators
Layout table for investigator information
Study Chair: Osama Rahma, MD Dana-Farber Cancer Institute
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Craig L Slingluff, Jr, Director of the UVA Human Immune Therapy Center, University of Virginia
ClinicalTrials.gov Identifier: NCT02305186    
Other Study ID Numbers: 17801
First Posted: December 2, 2014    Key Record Dates
Last Update Posted: August 13, 2021
Last Verified: August 2021
Keywords provided by Craig L Slingluff, Jr, University of Virginia:
Immunotherapy
Neoadjuvant
Resectable
Borderline resectable
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
 Endocrine System Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action